Another day, another subpoena. And the latest was sent to Shire last month by the US Department of Health and Human Services Office of Inspector General, which is working with the US Attorney in Philadelphia.
The focus of their interest is the sales and marketing practices for three ADHD drugs - Adderall XR, Daytrana and Vyvanse (see release). Specifics weren't disclosed, but Shire has aggressively promoted Vyvanse, a follow-up to Adderall XR, which began facing generic competition last April, The Pink Sheet notes. The Vyvanse campaigns include coupons.
For its part, Shire maintains there's no evidence of wrongoing, according to The Wall Street Journal. And Shire ceo Angus Russell is taking it all in stride. After all, many of his larger rivals are reaching settlements on a regular basis (see this). "We are a very regulated industry and it is becoming normal practice that from time to time companies of our size or bigger have inquiries from the government," the Journal quotes him as saying. "This is an inquiry. It is very early."